Abstract:Ling-ling Zhu, 1 Yan-hong Wang, 2 Jian-hua Feng, 3 Quan Zhou 2 1 VIP Geriatric Ward, Division of Nursing, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China; 2 Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China; 3 Department of Pediatrics, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China Correspondence: Quan Zhou, Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiefang Road No. 88, Hangzhou, 310009, Zhejiang Province, People's Republic of China, Email Jian-hua Feng, Department of Pediatrics, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiefang Road No. 88, Hangzhou, 310009, Zhejiang Province, People's Republic of China, Email Background: Bacterial lysates are known for having immunomodulatory properties and have been used mainly for the prevention and treatment of respiratory tract infections (RTIs). However, rigorous studies are needed to confirm the clinical efficacy of bacterial lysates with various bacterial antigen components, preparation methods, administration routes and course of treatment. OM-85, an oral standardized lysate prepared by alkaline lysis of 21 strains from 8 species of common respiratory tract pathogens, is indicated as immunotherapy for prevention of recurrent RTIs and acute infectious exacerbations of chronic bronchitis. OM-85 acts on multiple innate and adaptive immune targets and can restore type 1 helper T (Th1)/Th2 balance. Sporadic studies have shown advances in pharmacology and therapeutics of OM-85, and thus an update review is necessary. Methods: Literature was retrieved by searching PubMed, Web of science, Embase, CNKI, and Full Text Database of Chinese Medical Journals. Results: New roles of OM-85 were discovered in prevention and treatment of lung cancer, pulmonary tuberculosis, SARS-CoV-2 infection, allergic rhinitis, pulmonary fibrosis, atopic dermatitis, and nephrotic syndrome. Pharmacoeconomic values of OM-85 were demonstrated in prophylaxis and treatment of RTIs, chronic obstructive pulmonary disease, asthma, chronic bronchitis, rhinosinusitis and allergic rhinitis. Two consecutive courses of OM-85 (6 or 12 months apart) could prevent recurrent RTIs in children. Maternal OM-85 treatment could offer benefits for offspring. Product-specific response was observed. The efficacy of OM-85 may be associated with patient's characteristics (eg, severity of the disease, age, immune response pattern, malignancy risk stratification). Conclusion: OM-85 can improve effectiveness of standard care for some primary diseases, and carry significant pharmacoeconomic implications. The benefits shown by OM-85 in vitro and in vivo, when extrapolated to humans, are exciting but also require caution. Individualized treatment may need to be considered. It is necessary to compare the efficacy and safety of various bacterial lysate preparations. Keywords: airway inflammatory disease, allergic diseases, bacterial lysates, immunomodulator, OM-85, pharmacoeconomic evaluation Bacterial lysates (BLs) are mainly prepared from common microorganisms in human respiratory tract infections (RTIs) and several different brands are currently available in many countries. BLs are known for having immunomodulatory properties. They interact with dendritic cells in the mucous membranes of the upper respiratory tract and the gastrointestinal tract through toll-like receptors, allowing dendritic cells to present acquired antigens and promote the development of innate immune responses by releasing chemokines, thereby stimulating the maturation of monocytes and natural killer cells and promoting the migration of polymorphocytic neutrophils. In addition, they affect the adaptive immune system by stimulating an increase in specific antibodies against bacterial antigens. The effects of BLs include not only anti-inflammatory effects, but also restoring type 1 helper T (Th1)/Th2 balance and ameliorating the clinical manifestations of allergic diseases. 1 OM-85 (Broncho-Vaxom) is an oral immunomodulator containing extracts from eight bacterial pathogens (ie, Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae, Klebsiella odorosa, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans , and Neisseria catarrhalis ). 2 According to prescribing information, the indications of OM-85 are immunotherapy for prevention of recurrent infections of the airways and acute infectious -Abstract Truncated-

OM-85s anti-rhinovirus response assessed on human primary nasal epithelial cells

Lactobacillus rhamnosus dampens cytokine and chemokine secretion from primary human nasal epithelial cells infected with rhinovirus

Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics

OM-85 Broncho-Vaxom®, a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells

Pre-clinical development of a novel cross-protective rhinovirus vaccine.

Characterising the mechanism of airway smooth muscle β2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells

Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis

Euphorbium compositum SN improves the innate defenses of the airway mucosal barrier network during rhinovirus infection

Rhinovirus infection of the airway epithelium enhances mast cell immune responses via epithelial-derived interferons

Response to Rhinovirus Infection by Human Airway Epithelial Cells and Peripheral Blood Mononuclear Cells in an In Vitro Two-Chamber Tissue Culture System

Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells

Anionic Pulmonary Surfactant Lipid Treatment Inhibits Rhinovirus A Infection of the Human Airway Epithelium

Rhinovirus C15 Attenuates Relaxation and cAMP Production in Human Airways and Smooth Muscle

A role for anti-IL33 strategies to limit the epithelial rhinoviral response?

Preventive effects of prenatal administration of OM-85/BV on asthma and respiratory infection risk in the offspring: A review of animal models

Late response of bronchial epithelium to rhinovirus in severe asthma

Post-immunobiotics increase resistance to primary respiratory syncytial virus infection and secondary pneumococcal pneumonia

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations

Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study

Altered Differentiation and Inflammation Profiles Contribute to Enhanced Innate Responses in Severe COPD Epithelium to Rhinovirus Infection

Diesel exposure increases susceptibility of primary human nasal epithelial cells to rhinovirus infection